Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Longbio Pharma (Suzhou) CoHKSE:01779 +5.51%10 Current Ratio is 2.42 as of Dec. 2025, which is 30% above its 10-year median of 1.86. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100. Among 1,407 Biotechnology companies, Longbio Pharma (Suzhou) Co ranks worse than 62.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Longbio Pharma (Suzhou) Co's current ratio for the quarter that ended in Dec. 2025 was 2.42.
Longbio Pharma (Suzhou) Co has a current ratio of 2.42. It generally indicates good short-term financial strength.
The historical rank and industry rank for Longbio Pharma (Suzhou) Co's Current Ratio or its related term are showing as below:
HKSE:01779'
s Current Ratio Range Over the Past 10 Years
Min: 1.3 Med: 1.86 Max: 2.42
Current: 2.42
During the past 2 years, Longbio Pharma (Suzhou) Co's highest Current Ratio was 2.42. The lowest was 1.30. And the median was 1.86.
HKSE:01779's Current Ratio is ranked worse than 62.4% of 1407
companies
in the Biotechnology industry
Industry Median: 3.83
vs HKSE:01779: 2.42
Longbio Pharma (Suzhou) Co (HKSE:01779) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Longbio Pharma (Suzhou) Co Current Ratio Related Terms
Longbio Pharma (Suzhou) Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co Current Ratio Chart
Longbio Pharma (Suzhou) Co Annual Data
Trend
Dec24
Dec25
Current Ratio
1.30
2.42
Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24
Dec25
Current Ratio
1.30
2.42
HKSE:01779 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longbio Pharma (Suzhou) Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Longbio Pharma (Suzhou) Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Current Ratio of 2.42 as of Dec. 2025. This is 30% above median its historical median of 1.86. Over the past decade, Longbio Pharma (Suzhou) Co's Current Ratio has ranged from 1.30 to 2.42. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #878 out of 1407 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Longbio Pharma (Suzhou) Co's Current Ratio too high?
Longbio Pharma (Suzhou) Co's current Current Ratio of 2.42 is 30% above median its 10-year median of 1.86. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 2.42. The Biotechnology industry median Current Ratio is 3.83. Longbio Pharma (Suzhou) Co's value of 2.42 is 36.8% below this industry median. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #878 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #878 out of 1407 companies for Current Ratio. This places Longbio Pharma (Suzhou) Co in the lower half of its industry. The industry median Current Ratio is 3.83. Longbio Pharma (Suzhou) Co's value of 2.42 is 36.8% below this benchmark. Historically, Longbio Pharma (Suzhou) Co's own Current Ratio has ranged from 1.30 to 2.42 over the past decade. While the company's 10-year median is 1.86 vs. the industry median of 3.83, Longbio Pharma (Suzhou) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longbio Pharma (Suzhou) Co's current Current Ratio of 2.42 is 36.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longbio Pharma (Suzhou) Co's current Current Ratio is 2.42, which is 30% above median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Current Ratio of 2.42. The current Current Ratio is 2.42, which is 30% above median its 10-year median of 1.86 and 36.8% below the Biotechnology industry median of 3.83. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Current Ratio is 2.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score
Get the complete analysis for HKSE:01779
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01779 has been successfully added to your 
